geron corp News

geron corp News From AOL News

First Patient Has Experimental Stem Cell Procedure

(Oct. 11) -- A patient suffering from a spinal cord injury has become the first recipient of an experimental, and highly controversial, human embryonic stem cell treatment. Geron Corp., the biopharmaceutical group behind the phase I clinical trial, made the groundbreaking announcement earlier today. The company is the...

FDA OKs Embryonic Stem Cell Trials for Humans

For the first time, human subjects will be used to test a treatment of spinal cord injuries derived from embryonic stem cells, under rules approved by the Food and Drug Administration.

FDA Greenlights Geron to Begin First Human Trials of Embryonic Stem Cell Treatment

(July 30) -- The Food and Drug Administration has cleared biotech firm Geron to perform the first human trials of a medical treatment based on embryonic stem cells. Patients with recently sustained spinal cord injuries will be the first to undergo the company's stem cell therapy, called GRNOPC1. The trial was initially...

geron corp News From the Web

05/22/12 22 Biopharma Stocks With Breakout Potential in 2012 Source: TheStreet.com Drug approval decisions garner big headlines, but savvy and successful biotech investors know that making smart trading decisions ahead of important clinical trial results is the ticket to banking serious coin.
05/22/12 Stem Cell Hype Has Yet To Breed Profits Source: Seeking Alpha Over the past few years, stem cell therapies have emerged as an intriguing new frontier in biotechnology research as scientists have begun exploring ways to monetize stem cells' unique plasticity.
05/18/12 BioTime: A Track Record Of Broken Promises Source: Seeking Alpha Our extensive research has led us to conclude that BioTime ( BTX ) is grossly overvalued and that its shares should trade at a small premium to the company's cash balance - currently 45 cents per share.
05/09/12 Small Biotechs Like Aastrom Biosciences and Geron... Source: Marketwire Five Star Equities Provides Stock Research on Aastrom Biosciences and Geron NEW YORK, NY -- (Marketwire) -- 05/09/12 -- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation.
05/03/12 Geron Completes Enrollment in Phase 2 Clinical Trial... Source: Reuters Geron Corporation (Nasdaq: GERN) today announced that the company has completed planned enrollment of its randomized Phase 2 clinical trial of imetelstat, a telomerase inhibitor, as maintenance therapy following platinum-based induction therapy for patients with advanced non-small cell lung cancer (NSCLC).

Background on geron corp

Geron Corporation is a biotechnology company located in Menlo Park, California that specializes in developing and commercialization of products in three specific areas: 1) therapeutic products for cancer that inhibit telomerase; 2) pharmaceuticals that activate telomerase in tissues impacted by cell aging, injury or degenerative diseases; and 3) cell-based therapies derived from human embryonic stem cells for treatment of various chronic diseases.

more at wikipedia »